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TYROSINASE INHIBITOR IN FORTNER'S AMELANOTIC AND
MELANOTIC MALIGNANT MELANOMA*
GERALDINE J. ZDYBEK SATOH, Pn.D. AND YUTAKA MISHIMA, M.D., PH.D.
Although information has accumulated re-
garding the nature of tyrosinase and its role
in melanin pigmentation, very little is known
as to why there is almost complete absence of
melanization in the melanosome of amelanotic
malignant melanoma whereas the reverse is
true of melanotic malignant melanoma.
In 1946 Rothman and co-workers postulated
that the natural regulation of melanin for-
mnation may depend upon organic sulfhydryl
compound inhibition of tyrosinase, and demon-
strated an inhibitory factor in human epi-
dermis which could be released by specific
sulfhydryl poisons (1). Similar studies were
reported by Flesch in 1949 (2). Riley (3)
and Hirsch (4) reported an inhibitor of
dopa oxidase activity in mouse melanoma.
Identification and characterization of such
inhibitors has not been well defined.
The following is a report of a preliminary
study of tyrosinase inhibitor found in amelanotic
and melanotic malignant melanoma of the Syr-
ian golden hamster.
METHODS AND MATERIALS
Fortner's amelanotic malignant melanoma type
3 and Fortner's melanotic malignant melanoma
Lype 1 (5) were obtained from Joseph G. Fortner,
M.D., Sloan Kettering Institute, New York, and
transplanted thereafter in our laboratory. Ame-
lanotic melanoma type 3 had been preserved by
Fortner at low temperature under a nitrogen
atmosphere prior to our transplantation.
Syrian golden hamsters used for transplanta-
tion were obtained from Lakeview Hamster
Colony, Newfield, New Jersey, the same strain
as that used by Fortner,
Non-necrotic melanomas were homogenized in
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O.25M sucrose-0.02M phosphate buffer using a
Teflon head hand homogenizer, centrifuged at
700 X g to remove cell debri and then centrifuged
at 12,000 X g to obtain a soluble fraction. Tem-
peratures were maintained at 2°C. during this
preparation. All tumors were so processed unless
otherwise specified.
Studies of tyrosinase enzyme kinetics were
carried out in 1 cm cells in a Zeiss PMQ II spec-
trophotometer by the oxidation of L-3,4 dihy-
droxyphenylalanine (dopa) followed by measuring
the initial rate of increase in optical density at
475 millimicrons. The final reaction mixture con-
tained 0.5 /L mole/ml dopa and 35 mole/ml
phosphate buffer, pH 6.8.
RESULTS
Addition of soluble fraction of amelanotic
melanomas to that of the soluble fraction from
melanotic melanoma caused marked inhibi-
tion of melanotic melanoma tyrosinase activ-
ity as measured by the spectrophotometric
dopachrome formation utilizing L-dopa as
substrate. This is illustrated in Fig. 1. Line
A represents the soluble fraction of melanotic
melanoma equivalent to 0.06 g, where 5
mole of dopa is converted per hour per gram
melanoma. Line B represents the equivalent
amount of melanotic melanoma soluble frac-
tion (0.06 g) to which the soluble fraction of
amelanotic melanoma fraction is added equiva-
lent to 0.06 g amelanotic melanoma, where
3.36 mole dopa was converted per hour per
gram tumor or 33% decrease-.in activity. The
initial lag period becomes 15 minutes whereas
there was a 10 minute lag with melanotic mela-
noma alone. Adding amelanotic fraction equiva-
lent to 0.12 g of amelanotic melanoma reduced
the activity to 1.12 fL mole per hour per gram
melanotic melanoma or 78% decrease in activity,
as represented in line C. The lag period then
became 25 minutes.
Investigations were pursued to elucidate
whether this inhibitor was amelanotic mela-
noma specific. Inhibitory activity of soluble
fractions equivalent to 0.04 g, 0.08 g, and 0.12
g of original melanomas were measured utiliz-
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Fio. 1: Inhibition of melanotic tumor tyro-
sinase by amelanotic melanoma fraction plotted
as optical density at 475 mjz against minutes. Line
A represents soluble fraction of melanotic mela-
noma (0.06 g); B represents soluble fraction
melanotic tumor (0.06 g) + amelanotic soluble
fraction equivalent to 0.06 g melanoma; C repre-
sents soluble fraction of melanotic melanoma (0.06
g) + amelanotic soluble fraction equivalent to 0.12
g melanoma.
ing L-dopa as substrate and crystallized mush-
room tyrosinase as enzyme source. The linear
portion of mushroom tyrosinase from 30 sec-
onds to 1 minute and 30 seconds was used,
during which time interval no enzyme activ-
ity was contributed by melanotic fraction
since the lag phase of melanotic fraction was
at least 5 minutes. Fig. 2 indicates that the
percent of inhibition of mushroom tyrosinase
by amelanotic melanoma fraction is consider-
ably greater than that of melanotic melanoma,
there being 18% inhibition by amelanotic
fraction as compared to 11% by melanotic for
0.04 g melanoma respectively, 29% by amela-
notic compared to 13% by melanotic for 0.08
g melanoma respectively, and 37% by amel-
anotic as compared with 17% by melanotic
for 0.12 g melanoma. Therefore, although in-
hibitor effect is demonstrated by melanotic
melanoma, the inhibition is significantly more
pronounced in amelanotic melanoma.
In order to study further the properties of
this inhibitor, melanomas were homogenized
in 0.02 M phosphate buffer and a 12,000 x g
soluble fraction prepared. These fractions
were dialyzed against distilled water at pH
7.0 overnight. The diffusates were flash-evapo-
rated and then tested for their inhibitory ef-
fect on mushroom tyrosinase. Fig. 3 shows that
both melanotic and amclanotic diffusate equiv-
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Fio. 2: The percent of inhibition of mushroom
tyrosioase by melanotic and amelanotic soluble
fraction plotted against gram wet weight of
melanoma.
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Fm. 3: Inhibition of mushroom tyrosinase by
amelanotic and melanotic tumor diffusates plotted
as /h mole dopa converted/hour/0.l milligram
mushroom tyrosinase against gram wet weight
tumor equivalent.
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Fm. 4: Inhibition of melanotic soluble fraction
tyrosinase activity by amelanotic soluble frac-
tion, amelanotic and melanotic diffusate, and
amelanotic dialysate expressed as /L mole dopa
converted/hour/gram melanotic tumor equivalent.
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alent to 0.04 g, 0.08 g, and 0.1 g original
melanoma had quite similar inhibitory ef-
feet; therefore, 0.04 g had 33% inhibition,
0.08 g had 43% inhibition, and 0.1 g had 45%
inhibition. The dialysate had no inhibitory
effect toward mushroom tyrosinase or mela-
noma soluble fractions. Furthermore, the in-
hibitor from melanotic melanoma appears to
be bound as its inhibitory effect is much less
than that exhibited by amelanotic melanoma
whereas after dialysis the inhibitor from both
melanomas exerts very similar inhibitory ci.
feet.
Fig. 4 illustrates inhibition of soluble
fraction tyrosinase from melanotic melanoma
by soluble fraction from amelanotic melanoma,
and melanotic and amelanotic inhibitor iso-
lated from the diffnsate after dialyzing 12,000
x g melanoma homogenates. The dialysate of
amelanotic fraction no longer exhibits an in-
hibitory effect. Of most interest is the fact
that once inhibitor of melanotic melanoma is
freed by dialysis it is a potent inhibitor of
melanotic homogenate.
In summary, the following properties are
attributed to inhibitor obtained by dialysis of
12,000 x g homogenates of both melanotic and
amelanotic melanoma:
1. Heat stable.
2. Dialyzable.
3. Not extractable with acid butanol,
ether, chloroform, benzene.
4. Inhibitory effect on mushroom tyrosin-
ase unchanged by addition of Cn2, therefore
this substance appears not to be a sulfhydryl
compound.
5. Kinetic studies reveal the inhibitors to
be competitive.
Using mushroom tyrosinasc as an enzyme
source, the Michaelis-Menten constant of
mushroom tyrosinase was found to be 3.3 ><
10-4M, the K, of melanotic inhibitor 5.5 x
104M, and the K, of amelanotic inhibitor 4.2
x 104M. The K1 value of mushroom tyro-
sinase was close to that found for tyrosinase
from melanotic melanoma.
Further studies arc now in progress to iso-
late and identify these inhibitors.
CONCLUSION5
The defects in melanogenesis in amelanotie
melanoma may be attributed in part to dis-
turbed tyrosinase synthesis and the presence of
inhibitors since melanosome formation (6)
and active tyrosine release utilizable as sub-
strate bas been shown in amelanotic mela-
noma (7).
Fortner's amelanotic melanoma type 3 ex-
hibited no tyrosinase activity in 20 cases
presently studied. Furthermore, removing in-
hibitor from amelanotic fractions by dialysis
failed to reveal tyrosinase activity.
The characteristic properties of inhibitor
found in both melanotic and amelanotic
melanoma arc heat stability, dialyzable, not
a sulfhydryl compound, and competitive in-
hibition.
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